Denali Therapeutics shares rise as Q3 results beat expectations
DNLI Denali Therapeutics Inc
$20.07 +1.77%
View chart & analysis → - 1Denali Therapeutics Inc reported third-quarter results exceeding analyst expectations due to accelerating sales of its recently launched product AVLAYAH.
- 2Denali Therapeutics recorded a $0.74 beat against third-quarter consensus, leading to a 9.8% rise in Denali Therapeutics shares in Tuesday after-hours trading.
- 3CEO Ryan Watts said AVLAYAH is making a difference for children with Hunter syndrome and this quarter's results reflect that.
So what's the key point?
Denali Therapeutics Inc reported higher-than-expected results because its new product is selling well. The company earned $0.74 more than experts predicted, causing the stock price to rise 9.8%.
Source Investing.com +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.